Oct. 29, 2022

Ziftomenib: A Pioneering Menin-MLL PPI Inhibitor

ziftomenib

oral menin-MLL1 inhibitor Ph. I/II candidate in leukemia from HTS and SBDD Leukemia, Sep 23, 2022 Kura Oncology, San Diego, CA

twitterlinkedinprintemail